NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis

UnknownNA

Sponsor: Beijing Tongren Hospital

Conditions: Determination of the Efficacy of Different Medications for Idiopathic Rhinitis, Impact of Different Medications on Biomarkers of Idiopathic Rhinitis, Safety and Tolerance of Different Medications for Idiopathic Rhinitis

Interventions: Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.), Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.), 0.9% natural saline

Countries: China

Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Not younger than 18 years old
* Diagnosed as idiopathic rhinitis
* Signed and volunteered for the study

Exclusion Criteria:

* Comorbid airway diseases including (but not limited to) upper airway infection, chronic rhinosinusitis, nasal polyps
* Allergic to the medicines about to study
* Having used oral glucocorticoids or antihistamine agents within 30 days of the enrollment

Locations (2)

Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China